A US district court in Delaware has granted an interim injunction that will prevent Hospira from launching its generic version of Lexiscan (regadenoson injection) until 5 October, but said no to ...

Hospira isn't the only generics company trying to bring a version of regadenoson to the US market. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier this year.